Al-Ola A Abdallah MD (USMIRC) Profile picture
Jun 17, 2023 7 tweets 11 min read Read on X
Flame Cells: These are plasma cells with vermillion-staining glycogen-rich overstuffed fibrils. Although these cytoplasmic features are suggestive of neoplastic plasma cells, can also be found in reactive cells. imagebank.hematology.org/image/3230/fla… #mmsm #myeloma #MedTwitter #USMIRC #MedEd ImageImage
Mott cell is a plasma cell characterized by an accumulation of multiple Russell bodies, globular cytoplasmic inclusions composed of immunoglobulin imagebank.hematology.org/image/61837/mo… #mmsm #myeloma #MedTwitter #MedEd #USMIRC ImageImage
Russell bodies are cytoplasmic inclusions filled with immunoglobulins imagebank.hematology.org/image/4192/rus… #mmsm #myeloma #MedTwitter #MedEd #USMIRC ImageImage
Dutcher bodies (arrow) are intranuclear inclusions found in plasma cells. imagebank.hematology.org/image/1073/dut… #mmsm #myeloma #MedTwitter #MedEd #USMIRC ImageImage
inclusion bodies in plasma cells have been repeatedly reported, mainly concentrated in the Auer rod-like inclusions link.springer.com/article/10.100… #mmsm #myeloma #MedTwitter #MedEd #USMIRC ImageImage
Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Al-Ola A Abdallah MD (USMIRC)

Al-Ola A Abdallah MD (USMIRC) Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Abdallah81MD

May 27
🧵The Impact of Sponsors on Development of Clinical Research in Multiple Myeloma and AL Amyloidosis

1/Importance of Sponsoring Sources: Academic (AS), industrial (IS), & government sectors play crucial roles in funding and advancing medical research

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @OncoAlert @USMIRCNEWS #سرطان_الدم #المايلوماImage
2/Multiple Myeloma trials: Industrial trials constitute the largest proportion of MM trials (40%), followed closely by AS trials (37%).
Phase 2 trials are also the most common (61%), with AS leading in this phase (44%). However, industry significantly dominates both Phase 1 (54%) and Phase 3 (62%) MM trials. This suggests a greater industry focus on early-stage exploration and late-stage validation.

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @OncoAlert @USMIRCNEWS #سرطان_الدم #المايلوماImage
3/A much larger number of patients (112,419) enrolled in MM trials. IS trials accounted for the overwhelming majority of patient enrollment (65%), demonstrating a substantial dominance in this area. AS, NIHS, NS, and MS trials enrolled significantly fewer patients. Enrollment in IS trials has consistently led since 2001.

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @OncoAlert @USMIRCNEWS #سرطان_الدم #المايلوما
Read 8 tweets
May 10
🧵Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and
neurocognitive toxicity

1/ Cilta-cel-associated parkinsonism is a rare but serious delayed toxicity

*🚨Incidence reported in this study was 8% (5 cases out of the first 60 consecutive patients).
♾️ Previous studies cited show varying incidence rates: 6% in CARTITUDE-1, 1% in CARTITUDE-4, and 2% in commercial cilta-cel treatment.
#mmsm #myeloma #MedEd #medtwitter #USMIRC @USMIRCNEWS @OncoAlert #المايلوما #سرطان_الدمImage
2/🌡️ Characteristics of Cilta-cel-associated Parkinsonism: The onset is typically subacute, emerging approximately 1-2 months after CAR T-cell infusion.

**The median time to onset in this study was 26 days (range 9-36).
⚛️ Common symptoms observed in all 5 pts included personality changes (flat affect, anhedonia, avolition), difficulty with word finding, masked facies, anosmia, resting tremor, rigidity, impaired swallowing, micrographia, bradykinesia, & shuffling gait.

#mmsm #myeloma #MedEd #medtwitter #USMIRC @USMIRCNEWS @OncoAlert #المايلوما #سرطان_الدم
3/🧪 The study highlights the presence of CSF lymphocytosis, primarily comprised of T-cells, in patients experiencing MNTs.
- The median CSF WBC count was 42/μL (range 2-140), with 80% of patients showing CSF pleocytosis (>5 WBC/μL).
- The median CSF lymphocyte percentage was 90% (range 89-95%), with FC confirming these were almost exclusively T-cells.
- 🚦 This finding is significant as it suggests CAR T-cells are trafficking into the CSF.

#mmsm #myeloma #MedEd #medtwitter #USMIRC @USMIRCNEWS @OncoAlert #المايلوما #سرطان_الدم
Read 8 tweets
May 4
🚨🚨Very important Concept: ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human phase 1 study in RRMM:

1/ ISB 2001 is a novel trispecific TCE Ab designed to target three key antigens: BCMA & CD38 (on myeloma cells), & CD3 ( T-cell receptor complex)
#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوماImage
2/ ⚜️Study Design: ISB 2001 is administered weekly SC with a step-up dosing strategy (D1 & D4) followed by the full target dose (D8 onwards).
- Patient Population and Doses: 21 pts have been treated across 7 dose levels (5-1200 µg/kg).
- Across the effective dose levels (50-1200 µg/kg), the ORR was remarkably high at 89.5% (n=19).
ORR in patients previously treated w T-cell-directed therapy was 78% (n=9), suggesting efficacy even in this difficult-to-treat subgroup

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما
3/⚛️ PK data up to 1200 µg/kg showed a dose proportional increase in serum exposures. A tentative half-life of > 10 days was observed, which "supporting the potential for less-frequent dosing
- Pharmacodynamics & Biomarkers:Rapid Reduction in Serum sBCMA levels & circulating B-cell counts were reduced rapidly within the first 2 treatment cycles

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما
Read 6 tweets
Apr 23
🧵Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after
anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial

1/🚨Study Design: Single-centre, single-arm, phase 2 trial
• 37 patients with RRMM who had progressed after previous anti-BCMA CAR T-cell therapy, aged 18–70 years, with a Karnofsky Performance score ≥ 50.
*Patients were heavily pre-treated, with a median of 6 previous LOT. 59% had triple-class refractory disease!! (Not totally heavily treated IMO) ⚛️

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوماImage
2/Treatment: Single IV dose of anti-GPRC5D CAR T cells at 2 × 10⁶ cells per kg.
•Primary Endpoint: ORR based on IMWG.
•♦️Key Efficacy Finding: ORR was 84% (95% CI 68–94, 31 of 37 patients).
13 (35%) CR (8 sCR, 5 CR).

^^Response in Biochemical Progression: Responses were observed in 91% (10 of 11) of pts with only biochemical progression after anti-BCMA CAR T-cell therapy, including 64% (7 of 11) w CR

#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوماImage
Image
3/🧭 Comparison to Previous Salvage Therapies: In a post-hoc analysis of 14 patients who received subsequent antimyeloma therapies (CD38 antibody-based, carfilzomib-based, or selinexor-based) after anti-BCMA CAR T-cell progression, the ORR was 21% (3 of 14) 👎. The ORR of anti-GPRC5D CAR T-cell therapy in these same 14 pts was 71% (10 of 14), which was significantly higher (p=0·039). 👍🏻
- 20 (54%) of 37 patients achieved MRD-negativity.
- 🍋 mPFS in the entire cohort was 4·5 months (95% CI 2·9–6·2). PFS was not reached in pts with CR
#mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوماImage
Read 8 tweets
Apr 19
🧵A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

1/Real-World Effectiveness of Talquetamab:
- In 123 evaluable patients, the overall response rate was 65%, with 26% achieving a nCR or better.
- PFS was 6.4 months
- Median DOR was 12.7 months (95% CI 9.5–NE).
- Median OS was not reached at the time of data cutoff.
#mmsm #myeloma #USMIRC @USMIRCNEWS @OncoAlert #MedTwitter #MedEd #سرطان_الدم #المايلوماImage
2/High-Risk Patient Population:♣️
•43% had ISS stage III disease.
•37% had extraosseous disease.
•48% had high-risk cytogenetics.
•The median number of prior therapy lines was 6.
•58% of patients would not have been eligible for the MonumenTAL-1 trial based on its inclusion and exclusion criteria, primarily due to cytopenias, renal dysfunction, and recent anti-tumor therapies.
•86% were triple-class refractory, & 47% were penta-drug refractory.
•48% had prior exposure to T-cell redirecting immunotherapy, with 20% having received a prior BTCE (mostly teclistamab) and 34% prior CAR T-cell therapy.

#mmsm #myeloma #USMIRC @USMIRCNEWS @OncoAlert #MedTwitter #MedEd #سرطان_الدم #المايلوماImage
Image
3/♻️Safety Profile in Real-World Practice:
•CRS occurred in 70% of patients, with 5.1% experiencing grade ≥ 3 events.
•ICANS occurred in 9% of patients, with 1.5% experiencing grade ≥ 3 events.
•The rates of severe CRS & ICANS were numerically higher compared to the MonumenTAL-1 trial.

Compared to the trial cohort, lower rate of tocilizumab administrations (35% vs. 55%; p = 0.03) & an increased use of steroids (20% vs. 7%; p = 0.06).

#mmsm #myeloma #USMIRC @USMIRCNEWS @OncoAlert #MedTwitter #MedEd #سرطان_الدم #المايلوما
Read 7 tweets
Apr 16
💰💲Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma

💲Erlantamab cost over $19k/month!

1/ The estimated eligible population for elranatamab treatment within a one-million-member health plan is small: 14 patients per year for commercial plans and 60 patients per year for Medicare.
#mmsm #MedTwitter #MedEd #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوماImage
2/ The introduction of elranatamab is projected to increase total costs by $553,607 over three years, resulting in a per member per month (PMPM) increase of $0.05.

The total budget impact is estimated at $2,351,515 over three years, with a PMPM increase of $0.20

The primary driver of increased costs is the acquisition and administration of elranatamab, which replaces lower-cost regimens in the PCT basket.

#mmsm #MedTwitter #MedEd #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوماImage
3/Cost of Care Analysis (One-Year Horizon):Elranatamab had a total cost per patient of $337,838.

The cost per month of median PFS with elranatamab was $19,642

#mmsm #MedTwitter #MedEd #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(